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Purpose: We analyzed changes to the trends of prostate cancer management and 
patient characteristics at a single institute during 5 years due to the significant in-
crease of the prostate cancer incidence and the robotic equipment in Korea. Mate-
rials and Methods: Prostate cancer patient data from a single institute recorded 
from 2006 to 2010 were analyzed. Cancer stage, initial treatment modalities, and 
the pattern of outpatient clinical management were reviewed. Results: Between 
2006 and 2010, 386 prostate cancers were newly diagnosed at the institute. The 
proportion of localized and locally advanced cancer cases increased from 67% in 
2006 to 79% in 2010 respectively. Among the treatment choices during follow-up 
in the out-patients clinic, the proportion of radical prostatectomies increased from 
43% in 2006 to 62% in 2010. In contrast, the proportion of hormone therapies de-
creased from 58% to 37%. For initial treatment choice, radical prostatectomy was 
chosen for 59% of the patients who were newly diagnosed with cancer during the 
study period. However, hormone therapy alone was administrated as a primary 
therapy to 26%. Analysis of the radical prostatectomy subgroup showed that a ro-
bot-assisted technique was used in 83% of the patients, and the remaining 17% un-
derwent an open radical prostatectomy. Conclusion: As the prostate cancer inci-
dence increased in Korea, the proportion of localized and locally advanced cancer 
also increased. In addition, the main treatment modality changed from non-surgi-
cal treatment to radical prostatectomy.
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INTRODUCTION
Prostate cancer is the most common cancer among men in Western countries and 
the associated mortality has been high since the 1990s.1 In contrast, prostate cancer 
was not regarded as an issue in Asia due to a low incidence rate.2 However, a re-
cent rapid increase in the incidence of prostate cancer in Asia has drawn the atten-
tion of many urologists in Asia to investigate new treatments for prostate cancer 
and to actively participate in prostate cancer studies. 
In Korea, the prevalence of prostate cancer has quadrupled from 2002 to 2008, 
and the increased incidence rate is highest in total forms of malignancy.3 Environ-
mental elements, such as increased population age due to the rise in average life 
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For this present analysis, patients were stratified into lo-
calized prostate cancer (LPC), locally advanced prostate 
cancer (LAPC), advanced prostate cancer (APC), and hor-
mone refractory prostate cancer (HRPC) based on the 
pathologic stage. The initial management of prostate cancer 
after diagnosis was also stratified into retropubic radical 
prostatectomy (RRP), robot assisted laparoscopic radical 
prostatectomy (RALP), radiotherapy (RT) only, radiothera-
py with hormone therapy (RT+HT), primary hormone ther-
apy (HT), and watchful waiting (WW). For the analysis of 
the trend change in prostate cancer, the proportion of treat-
ments for prostate cancer patients by operation (OP), 
OP+RT, OP+HT, RT, RT+HT, HT, and WW in the outpa-
tient clinic registration database were assessed within the 
designated study period. 
RESULTS
 
In total, 546 men were registered with prostate cancer in 
our institute from January 2006 to November 2010. These 
patients visited 9053 times for prostate cancer treatment 
during the study period. Among them, total 417 men were 
newly diagnosed during the study period. Another 129 men 
were diagnosed and registered before 2006. of the 417 pa-
tients newly diagnosed, 17 patients were lost after prostate 
cancer diagnosis using the prostate biopsy and 14 patients 
were registered in our institute for a second opinion and 
were lost after just one visit. The newly diagnosed prostate 
cancer patients during study period comprised 386 men. 
Between 2006 and 2010, the number of prostate cancer 
registrations increased more than 2 times from 173 to 408 
men. The proportion of LPC and LAPC increased from 
67.6% in 2006 to 79.1% in 2010. However, the total num-
ber of APC and HRPC patients showed no significant 
change, and actually declined from 33% to 21% (Fig. 1).
In newly diagnosed patients, the prostate cancer stage 
classifications were 43.5% LPC, 36% LAPC, and 20.4% 
APC. According to the distribution of initial management 
chosen by the patients, the proportion of men undergoing 
RALP was 48.9% and 10.3% opted for RRP; 10.6% of pa-
tients chose RT+HT as the initial treatment, and 26.4% 
chose primary HT. 
In the LPC group, the distribution of initial management 
modalities was 59.5%, 11.9%, 7.1%, and 13.7% treated 
with RALP, RRP, RT with HT, and primary HT, respective-
ly. In the LAPC group, the distribution of initial manage-
expectancy, change to Western dietary habits, medical devel-
opment of laboratory diagnosis and prostate-specific antigen 
(PSA) screening campaigns by the Korean Urologic Associ-
ation (KUA) and other health organizations have helped to 
publicize the increase in prostate cancer in Korean patients.4,5 
Moreover, the introduction of robotic surgery in 2006 has in-
creased the awareness of prostate cancer in the general public 
and provided another option for the management of patients 
with prostate cancer. 
Despite the increase of the prostate cancer incidence and 
the emergence of the robotic system in Korea, there are no 
recent published data regarding the practical and clinical 
changes in Korean prostate cancer patients. Therefore, we 
analyzed the database of registered prostate cancer patients 
from 2006 to 2010 in our outpatient clinic to investigate 
changes in clinical characteristics and the trends of prostate 
cancer management in order to generate a preliminary re-
port for the Korean prostate cancer population.
MATERIALS AND METHODS
　　　
We analyzed a database of prostate cancer patients in the out-
patient clinic from January 2006 to November 2010. Patients 
who registered for a second opinion for prostate cancer treat-
ment and those patients that were lost after diagnosis were 
excluded from the study. Data including information on pa-
tient demographics, disease staging, choice of initial manage-
ment and treatment of follow-up course were reviewed. 
Pathologic staging and clinical staging were determined in 
accordance with TNM categories as published in 2003. 
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Fig. 1. Increase in prostate cancer patients in the outpatient clinic between 
2006 and 2010.
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patients increased by 79% in 2010 compared to 67% in 
2006. Second, the proportion of operations including RALP 
and RRP as initial treatment choice was the highest in com-
parison to other treatments. Lastly, this result brought about 
the gradual increase of the patients who had underwent op-
erations as the main treatment modality in outpatient clinics. 
This also drove the patients who treated with the adjuvant 
therapy including RT or HT due to biochemical recurrence 
to increase gradually. In contrast, we found that the number 
of the patients who chosen primary HT had decreased. We 
ment techniques was 64%, 14.4%, 12.2%, and 8.6% for 
RALP, RRP, RT with HT, and primary HT, respectively. 
With the LPC and LAPC groups, WW was chosen by only 
4.5% as the initial treatment for the prostate cancer (Fig. 2). 
The trends for prostate cancer patients registered at our 
outpatient clinic are shown in Fig. 3. In 2006, 43.4% of pa-
tients were followed-up in our outpatient clinic after opera-
tion (RRP or RALP) with or without biochemical recurrence 
as the main treatment modality. Per annum, this proportion 
steadily increased to 51.9%, 56.8%, 60.3%, and 61.5%. By 
contrast, the primary HT group declined from 41% in 2006 
to 23% in 2010.    
DISCUSSION
Many reports have documented RALP is the choice of treat-
ment for the localized prostate cancer. In the United States, 
RALP was performed only 10% of the total number of radi-
cal prostatectomies in 2006. However, the proportion had in-
creased to more than 65% in 2008 through 2009.6 The same 
phenomenon was also reported in Korea, where RALP was 
increased dramatically from 8% to 77% between 2005 and 
2008.7 In Korea, robot-assisted laparoscopic radical prosta-
tectomy using the DaVinci® robotic system (intuitive surgical 
Inc., Sunnyvale, CA, USA) was introduced in 2005. 
According to a 2010 report from the National Evidence-
based Healthcare Collaborating Agency, Korea becomes the 
fifth largest nation in the world with robotic surgical equip-
ment. They reported that after the Korean Food and Drug 
Administration (KFDA) approval in 2005, the urologic ro-
bot surgery performance cases were estimated to be 6000 
cases on October, 2010.8 However, during the study period, 
we performed RALP in only 189 cases after equipment of 
the robotic system, even though our institute became the 
second in Korea to initiate the use of robotic surgery in 2007. 
According to report form the Health and Welfare statistics,9 
the large number of the patients who newly diagnosed pros-
tate cancer is registered for treatment in hospitals that rank 
among the top 4 urologic departments in Korea. For this 
reason, most RALP have been performed intensively in a 
limited number of hospitals in Korea. Nevertheless, we 
found interesting changes in the clinical characteristics and 
trends of prostate cancer management. 
First, the registration of prostate cancer patients in our in-
stitute has increased more than 2 times during 5 years. Es-
pecially in LPC and LAPC, the number of prostate cancer 
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Fig. 2. Proportion of initial treatments between 2006 and 2010 according to 
pathologic stage (HT, hormone therapy; RT+HT, radiation therapy with hor-
mone therapy; RRP, retropubic radical prostatectomy; RALP, robot-assisted 
laparoscopic radical prostatectomy; WW, watchful waiting). LAPC, locally 
advanced prostate cancer; LPC, localized prostate cancer; APC, advanced 
prostate cancer.
Fig. 3. Treatment trends in prostate cancer patients in the outpatient clinic 
between 2006 and 2010. HT, hormone therapy; RT, radiotherapy; OP, opera-
tion; WW, watchful waiting.
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that the main treatment after diagnosis of prostate cancer is 
radical prostatectomy including RRP and RALP. This find-
ing is not true for only our institute.7 The advantages of ro-
botic surgery are introduced to patients intensively by the 
mass media, and radical surgery for prostate cancer is simul-
taneously advertised as a definite curative option. Moreover, 
Korean cancer patients tend to prefer a complete cure with 
a radical operation over daily hormonal medications and 
monthly hormonal injections. This trend would decrease 
the proportion of primary HT gradually in Korea.  
Recently, the National Comprehensive Cancer Network 
published an Asian Consensus Statement on prostate can-
cer. In statement, 10 the treatment options for patients with 
negative metastasis are listed in order of preference as 
RT+HT, HT, and observation.15 However, considering all of 
the findings; this statement is not consistent with the pres-
ent analysis. Our present analysis shows that the practical 
guidelines for treating prostate cancer support operations 
over a pharmacologic, radiation, or conservative manage-
ment. Our trend of prostate cancer management is similar 
to that in the United States16 and there is a vast difference 
with regard to initial management preference compared to 
Japan, despite its close geographic proximity.13  
The present study has some limitations. The period for 
analysis needs to be followed-up for longer than 2006 in or-
der to analyze the trend of prostate cancer incidence for the 
early 2000s, and the database of our institute does not rep-
resent the entire status of the Korean population. To over-
come these limitations, data form a large-scale observational 
longitudinal study cohort such as the cancer of the prostate 
strategic urologic research endeavor (CaPSURE) in United 
States is needed.17 The CaPSURE represents not only Unit-
ed States but also serves as one of the most famous and rep-
utable study groups in the scope of urology. Japan also has 
a large-scale database of observational longitudinal data to 
investigate safe and effective hormone therapy in prostate 
cancer patients.18 Although the Japan study group of pros-
tate cancer (J-CaP) does not represent the entire status of 
prostate cancer in Japan, they could represent trend and 
characteristics of primary hormone therapy in Japanese 
prostate cancer patients can be investigated. There is still no 
large-scale database being used to determine the nation-
wide trend of the management and changes in the clinical 
characteristics in Korea. However, we believe that a large 
Korean prostate cancer database will come soon and prove 
the change of the prostate cancer trend in Korea like our 
present study.
suspected that these changes were due to not only the effect 
of the robotic surgery system but also the increase of the 
prostate cancer incidence in Korea.
Recently, the increase in the rate of prostate cancer was 
reported at almost 12% per annum, which is the highest 
rate increase relative to the five major cancers in Korean 
men including stomach cancer, colon cancer, lung cancer, 
liver cancer, and prostate cancer.3 The prevalence rate of 
prostate cancer has increased threefold from 5.5 men out of 
100000 in 2000 to 14.3 men out of 100000 in 2005.3 Ac-
cording to the National Health Insurance Corporation, the 
number of prostate cancer patients in outpatient clinics in-
creased from 4843 men in 2002 to 20498 men in 2010.9          
The number of prostate cancer patients in Korea increased 
sharply due to a rapid increase in the elderly population, a 
change in dietary habits to a Western-like diet, the develop-
ment of diagnostic techniques using PSA, the continuous 
promotion of prostate cancer by the mass media, and the 
BLUE RIBBON campaign for PSA screening organized by 
the KUA. The Korean government does not include pros-
tate cancer in the free cancer-screening program as of yet, 
but if this does occur, the increase in prostate cancer inci-
dence is expected to increase. For these reasons, the detec-
tion of prostate cancer could be more likely in earlier stages 
in men. An increase of the early diagnosis in younger men 
at the LPC and LAPC stage would allow the patients to 
consider operations including RALP and RRP as the initial 
management tool. 
The proportion of WW as the initial therapy was only 
3.6% in the total group (14 of 386 patients). In 14 patients, 
13 patients were LPC stage. The proportion of WW was 
similar to the results reported from Japan and the United 
States.10,11 In contrast, conservative treatment including 
WW was the main modality in low risk LPC in the United 
Kingdom.12 In Korea, despite the indolent nature of prostate 
cancer, patients strongly desire definite treatment for a com-
plete cure and urologists do not want to face legal problems 
if the disease progresses without treatment even though 
WW is an option for prostate cancer. Therefore, the United 
Kingdom-like trend for prostate cancer management is not 
available in Korea.
We found a different approach to prostate cancer treat-
ment when comparing with Japan. The authors of a Japa-
nese study reported that the initial choice of treatment for 
prostate cancer was mainly primary HT.13 Hinotsu, et al.14 
reported that primary HT has been used in Japan for over 
80% of low-risk patients. However, our findings indicate 
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